These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 7743459

  • 21. [Platelet-activating factor (PAF) receptor-related pathophysiology].
    Ishii S, Shimizu T.
    Tanpakushitsu Kakusan Koso; 1999 Jun; 44(8 Suppl):1068-74. PubMed ID: 10396985
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC, Seldon PM, Barnes PJ, Giembycz MA.
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [Abstract] [Full Text] [Related]

  • 23. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 24. Membrane and intracellular platelet-activating factor receptor expression in leukemic blasts of patients with acute myeloid and lymphoid leukemia.
    Donnard M, Guglielmi L, Turlure P, Piguet C, Couraud MJ, Bordessoule D, Denizot Y.
    Stem Cells; 2002 Mar; 20(5):394-401. PubMed ID: 12351810
    [Abstract] [Full Text] [Related]

  • 25. The bioregulatory role of platelet-activating factor in intracellular processes and cell-cell interactions.
    Kulikov VI, Muzya GI.
    Biochemistry (Mosc); 1998 Jan; 63(1):47-54. PubMed ID: 9526094
    [Abstract] [Full Text] [Related]

  • 26. FR128998 ameliorates liver injury in extended liver resection with ischemia in dogs.
    Iwazaki S, Takeyoshi I, Ohwada S, Sunose Y, Tsutsumi H, Kawashima Y, Matsumoto K, Morishita Y.
    Hepatogastroenterology; 2001 Jan; 48(37):197-202. PubMed ID: 11268964
    [Abstract] [Full Text] [Related]

  • 27. In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation.
    Bastos da Silva M, Delaunois A, Gustin P, Godeau JM, Lekeux P.
    Vet Res; 2000 Jan; 31(2):267-72. PubMed ID: 10779205
    [Abstract] [Full Text] [Related]

  • 28. Platelet-activating factor: a novel lipid agonist.
    Hanahan DJ.
    Curr Top Cell Regul; 1992 Jan; 33():65-78. PubMed ID: 1323447
    [No Abstract] [Full Text] [Related]

  • 29. Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis.
    Curtis LD.
    Adv Exp Med Biol; 1996 Jan; 416():361-3. PubMed ID: 9131174
    [No Abstract] [Full Text] [Related]

  • 30. Preclinical and clinical pharmacology of platelet-activating factor receptor antagonists.
    Handley DA.
    Med Res Rev; 1990 Jan; 10(3):351-70. PubMed ID: 2164623
    [No Abstract] [Full Text] [Related]

  • 31. NHLBI workshop summary. Platelet-activating factor: role in pulmonary injury and dysfunction and blood abnormalities.
    Henson PM, Barnes PJ, Banks-Schlegel SP.
    Am Rev Respir Dis; 1992 Mar; 145(3):726-31. PubMed ID: 1312316
    [No Abstract] [Full Text] [Related]

  • 32. Platelet-activating factor: antagonists, terminators, molecular mimics, and microbial opportunism.
    Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM.
    J Intern Med; 1996 Jun; 239(6):463-6. PubMed ID: 8656138
    [No Abstract] [Full Text] [Related]

  • 33. Platelet activating factor and asthma.
    Barnes PJ.
    Ann N Y Acad Sci; 1991 Jun; 629():193-204. PubMed ID: 1659278
    [No Abstract] [Full Text] [Related]

  • 34. Lipid mediators stimulate reactive oxygen species formation in immortalized human keratinocytes.
    Goldman R, Moshonov S, Zor U.
    Adv Exp Med Biol; 1999 Jun; 469():413-8. PubMed ID: 10667361
    [No Abstract] [Full Text] [Related]

  • 35. Characterization of the physicochemical properties of the micelles by the novel platelet activating factor receptor antagonist E5880.
    Asai Y, Watanabe S.
    Eur J Pharm Biopharm; 2000 May; 49(3):219-23. PubMed ID: 10799812
    [Abstract] [Full Text] [Related]

  • 36. An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.
    Bazill GW, Dexter TM.
    Biochem Pharmacol; 1989 Jan 15; 38(2):374-7. PubMed ID: 2536543
    [No Abstract] [Full Text] [Related]

  • 37. Antitumor ether lipids: endocytosis as a determinant of cellular sensitivity.
    Workman P.
    Cancer Cells; 1991 Aug 15; 3(8):315-7. PubMed ID: 1657088
    [No Abstract] [Full Text] [Related]

  • 38. Biochemistry of platelet-activating factor: a unique class of biologically active phospholipids.
    Snyder F.
    Proc Soc Exp Biol Med; 1989 Feb 15; 190(2):125-35. PubMed ID: 2536942
    [No Abstract] [Full Text] [Related]

  • 39. Resisting resistance with PAF receptor antagonists.
    Jarvis GE.
    Trends Pharmacol Sci; 2002 Mar 15; 23(3):110. PubMed ID: 11879675
    [No Abstract] [Full Text] [Related]

  • 40. Bioactive lipids and gene expression in neuronal plasticity.
    Bazan NG.
    Adv Exp Med Biol; 1998 Mar 15; 446():37-49. PubMed ID: 10079836
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.